Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00624351 · ClinicalTrials.gov registry record · Phase 2
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT00624351: Completed Phase 2 study of Systemic Lupus Erythematosus, sponsored by UCB Pharma.
NCT00624351 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by UCB Pharma. The registered enrollment target is 227 participants, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00624351, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
Primary Outcome
The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Epratuzumab
Study Locations (20)
North Carolina
- - Chapel Hill
- - Charlotte
- - Durham
- - Wilmington
California
- - La Jolla
- - Los Angeles
- - San Leandro
Florida
- - Aventura
- - Tampa
Alabama
- - Birmingham
Arizona
- - Tucson
Colorado
- - Denver
Connecticut
- - Farmington
Maryland
- - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00624351 record still lists
NCT00624351 is an interventional study that assigns participants to a tested intervention. The registered 227 participants enrollment target is mid-sized for trials with a published cap, below the 378-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00624351 names 20 study sites across 14 states, led by North Carolina, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00624351 about?
NCT00624351 is a clinical study titled "Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease". The primary objective of the study is to assess the dose response and the dose frequency of epratuzumab in patients with SLE.
What is the current status of trial NCT00624351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2008-01. Estimated completion is 2009-08.
What conditions does trial NCT00624351 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00624351?
The interventions under investigation include: Placebo (OTHER), Epratuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00624351?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00624351 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00624351's enrollment target sits among peer trials
227 36th of 99 higher than 64 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04751409 · 227 participants · Phase 2
Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- NCT05742360 · 227 participants
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
- NCT05890352 · 227 participants · Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia